Sevelamer Carbonate Tablet
Product Images NDC 64380-872

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Sevelamer Carbonate (NDC 64380-872). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Strides Pharma Science Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Description (404ae0dd 9a7d 4199 9647 D7c6b9d3c281 01)

Chemical structure diagram of sevelamer carbonate, showing polymeric units with ammonium, bicarbonate groups, and hydroxyalkyl amine components arranged in a repeating pattern.*

FDA Label Image

Figure-2 (404ae0dd 9a7d 4199 9647 D7c6b9d3c281 02)

A subgroup analysis forest plot depicting the comparison of sevelamer carbonate versus placebo. The x-axis shows the effect size, ranging from favoring sevelamer carbonate to favoring placebo. Various subgroups are listed on the y-axis, including screening BSA, baseline serum phosphorus levels, age, and dialysis status. Each subgroup shows a point estimate with confidence intervals, along with sample sizes and 95% confidence intervals for mean differences.*

FDA Label Image

Figure 2 (404ae0dd 9a7d 4199 9647 D7c6b9d3c281 03)

A line chart depicting the percentage of patients achieving at least a twofold reduction in serum phosphorus levels (mg/dL) comparing sevelamer hydrochloride and an active control. The x-axis represents reduction in serum phosphorus from baseline (negative to positive values), and the y-axis shows the percentage of patients, decreasing from 100% to 0%. Annotations indicate worsening or improvement in phosphorus reduction.*

FDA Label Image

Image (404ae0dd 9a7d 4199 9647 D7c6b9d3c281 04)

A line graph showing the change in phosphorus levels from baseline over a 52-week study period. The x-axis represents study weeks from 0 to 52, and the y-axis shows phosphorus change from baseline ranging from -5 to 2. Two lines represent treatment groups: Sevelamer Hydrochloride (solid black squares) and Active-Control (open red squares), depicting trends in phosphorus reduction during the study.*

FDA Label Image

Container Label (30S)

Label for SEVELAMER CARBONATE tablets, 800 mg oral dosage form by Strides Pharma Science Limited. The label includes the active ingredient sevelamer carbonate 800 mg per film-coated tablet, inactive ingredients, storage instructions, package size of 30 tablets, and manufacturer/distributor information including Strides Pharma Inc. and Strides Pharma Science Ltd. barcodes and NDC 64380-872-04 are also visible.*

FDA Label Image

Container Label 270s (404ae0dd 9a7d 4199 9647 D7c6b9d3c281 06)

Label for Sevelamer Carbonate Tablets, 800 mg oral film-coated tablets, with 270 tablets per container. Active ingredient is sevelamer carbonate 800 mg. Produced by Strides Pharma Science Ltd., India, and distributed by Strides Pharma Inc., New Jersey, USA. The label includes storage instructions and a reference to see package insert for dosage information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.